PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer

Pharmacologic inhibition of PARP is the primary therapeutic strategy for BRCA mutant ovarian cancer. However, most of patients carry wild-type BRCA1/2 with no significant clinical benefits from PARP inhibitors, calling for the needs to further understanding and developing new strategy when employing...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Redox Biol
Main Authors: Hong, Ting, Lei, Guang, Chen, Xue, Li, He, Zhang, Xiaoye, Wu, Nayiyuan, Zhao, Yu, Zhang, Yilei, Wang, Jing
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2021
Assuntos:
Articles from the Special Issue on Redox Modulation of Cancer Heterogeneity, Therapeutic Resistance and Immunotherapy Efficacy; Edited by Dr. Anita Hjelmeland
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8113041/
https://ncbi.nlm.nih.gov/pubmed/33722571
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.redox.2021.101928
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados